Posted On: 09/20/2014 11:37:01 AM
Post# of 30067
Chris: I think Jason has put that number out there. It is dramatically better! Without betting on MANF for PD, which is more complex, I'd give MANF's chances for FDA approval on Retintis....1 in 2?
Obviously, we hope the odds are even better than that. But, to assume we have a lock on FDA approval at this early stage would be....dangerous.
That's why I love Lympro. LymPro, in my opinion, will be earning revenue within a few months. I don't know how well it will do, but it will do well enough to make my investment in AMBS far less risky, than if AMBS only had MANF, alone.
That is why I often say it is Lympro that brought me here. Not because Lympro has more potential than MANF, but in my opinion, it has less chance of failure.
Obviously, we hope the odds are even better than that. But, to assume we have a lock on FDA approval at this early stage would be....dangerous.
That's why I love Lympro. LymPro, in my opinion, will be earning revenue within a few months. I don't know how well it will do, but it will do well enough to make my investment in AMBS far less risky, than if AMBS only had MANF, alone.
That is why I often say it is Lympro that brought me here. Not because Lympro has more potential than MANF, but in my opinion, it has less chance of failure.
(0)
(0)
